Aventis Company Profile

11:56 EST 24th November 2017 | BioPortfolio

Aventis is dedicated to improving life through the discovery and development of innovative pharmaceutical products.

We offer a range of patented prescription drugs to treat patients with serious diseases and have leading positions in a number of therapeutic areas, including respiratory/allergy, cardiology/thrombosis, oncology and diabetes. We are also world leaders in the areas of human vaccines and therapeutic proteins.

Aventis has two products with sales of more than € 1 billion and two additional products with sales of more than € 500 million that are fast approaching blockbuster status. Several other products have significant potential, and we are focusing our marketing and sales activities on this group of “strategic brands.”

Our pipeline is full with a number of therapeutic innovations in development, including compounds for the treatment of diabetes and cancer as well as respiratory and cardiovascular diseases. More than 5,000 scientists at sites in France, Germany, Japan and the United States are expanding our leading position in the discovery and development of new drugs.

Aventis is dedicated to creating and delivering products of unquestionable quality that enable people to live longer, healthier and more active lives. In this spirit, we encourage our employees to care for each other’s well being and protect the environment in all aspects of their lives. We are committed to the principles of sustainable development, which is demonstrated by our participation in the U.N. Global Compact.

Aventis was created through the December 1999 business combination of Hoechst and Rhône-Poulenc. We are transforming Aventis into a pure pharmaceutical company through the divestiture of the Aventis CropScience and Aventis Animal Nutrition businesses as well as the remaining industrial activities. Along with our pharmaceutical business, Aventis will retain a 50% stake in the animal health business Merial, a joint venture with Merck & Co. (accounted for using the equity method).


Cedex 9
United Kingdom


Phone: +33-388-99-1100
Fax: 33 (0) 3 8899 1375

News Articles [21 Associated News Articles listed on BioPortfolio]

sanofi-aventis’ New Direction

Since Chris Viehbacher joined sanofi-aventis as CEO his aim has been to get the company recognised as a global healthcare company and not solely as a producer of vaccines. Jean-Claude Muller, Senior V...

Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression...

The Transformation Of Sanofi-Aventis U.S.

The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. By Dan Schell, Life Science Leader magazine

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Animal Health JV, PTV News: Mar 09, 2010

Merck & Co. and sanofi-aventis target US$ 19B market

Pre-clinical Deal, PTV News: Apr 08, 2010

Sanofi-aventis pact with CureDM to develop novel diabetes drug

€105M Deal, PTV News: May 19, 2010

Sanofi-aventis buys Polish consumer healthcare group Nepentes

Cancer Trial Results, PTV News: Mar 05, 2010

Dendreon's Provenge and sanofi-aventis' Cabazitaxel show positive data

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.

To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME).

Clinical Trials [37 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)

SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antith...

: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery

To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in postoperative cardiac surgery patients by comparing plasma anti-Xa activity when enoxaparin is administered ...

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

A randomized, double-blind, placebo-controlled parallel-group study, comparing the bioequivalence of triamcinolone acetonide aqueous nasal spray (Apotex, Inc.) to that of Nasacort® AQ nas...

Bioavailability Study of Leflunomide Tablets Under Fed Conditions

To compare the single-dose Bioavailability of Kali and Aventis

Companies [46 Associated Companies listed on BioPortfolio]

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

Merck and sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...

Sanofi SA

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.

Ascenta Therapeutics

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) ...

More Information about "Aventis" on BioPortfolio

We have published hundreds of Aventis news stories on BioPortfolio along with dozens of Aventis Clinical Trials and PubMed Articles about Aventis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aventis Companies in our database. You can also find out about relevant Aventis Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Corporate Database Quicklinks

Searches Linking to this Company Record